By partnering with German biotech Evotec AG, Sanofi has increased its options for finding viable drugs against infectious diseases at a lower cost than if it did it on its own, the German biotech's CEO told Scrip.
Werner Lanthaler also said it's an avenue that other big pharma companies should explore if they are serious about helping...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
